Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM580GT)

• Drug Name: Xanamem Drug Info
• Synonyms: Xanamem; UE2343; 1346013-80-6; (5-(1H-Pyrazol-4-yl)thiophen-3-yl)((1R,3r,5S)-3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone; starbld0030988; SCHEMBL23207782; SCHEMBL23798797; GTPL12037; GLXC-26582; compound 4 [PMID: 28012176]; UE-2343; [(1S,5R)-3-hydroxy-3-pyrimidin-2-yl-8-azabicyclo[3.2.1]octan-8-yl]-[5-(1H-pyrazol-4-yl)thiophen-3-yl]methanone

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1/2	[1]

• Cross-matching ID:
  PubChem CID: 137530063
  TTD Drug ID: DM580GT

Molecule-Related Drug Atlas

Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLYCYRRHIZIN	DM8M2N3	Influenza virus infection	1E30-1E32	Phase 3	[3]
BVT.2733	DM6RUKX	Lupus	4A40	Phase 3	[4]
INCB13739	DMLQ3PO	Type-2 diabetes	5A11	Phase 2a	[5]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[6]
JTT-654	DM50M2R	Type-2 diabetes	5A11	Phase 2	[7]
RG-4929	DMT4QRD	Metabolic disorder	5C50-5D2Z	Phase 2	[7]
BMS-770767	DMTVGY7	Hypercholesterolaemia	5C80.0	Phase 2	[7]
UE-2343	DMIERPK	Alzheimer disease	8A20	Phase 2	[8]
AZD-4017	DML9M5S	Ocular hypertension	9C61.01	Phase 2	[7]
BMS-816336	DM2WMJ7	Lipid metabolism disorder	5C52.Z	Phase 1	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	TTN7BL9	DHI1_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04983368) XanaMIA-DR A Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Pharmacodynamics and Safety of Xanamem? in Healthy Elderly Volunteers. U.S.National Institutes of Health.
• [2] Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.
• [3] Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
• [4] Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
• [5] Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
• [6] 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
• [7] New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027626)